These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 16282216)

  • 21. Comparison of cost-of-illness with willingness-to-pay estimates to avoid shigellosis: evidence from China.
    Guh S; Xingbao C; Poulos C; Qi Z; Jianwen C; von Seidlein L; Jichao C; Wang X; Zhanchun X; Nyamete A; Clemens J; Whittington D
    Health Policy Plan; 2008 Mar; 23(2):125-36. PubMed ID: 18234703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y
    Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
    Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disentangling WTP per QALY data: different analytical approaches, different answers.
    Gyrd-Hansen D; Kjaer T
    Health Econ; 2012 Mar; 21(3):222-37. PubMed ID: 21254305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using willingness to pay to measure family members' preferences in mental health.
    Mulvaney-Day NE
    J Ment Health Policy Econ; 2005 Jun; 8(2):71-81. PubMed ID: 15998979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diminishing willingness to pay per quality-adjusted life year: valuing acute foodborne illness.
    Haninger K; Hammitt JK
    Risk Anal; 2011 Sep; 31(9):1363-80. PubMed ID: 21488924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Willingness to pay for dentin regeneration in a sample of dentate adults.
    Birch S; Sohn W; Ismail AI; Lepkowski JM; Belli RF
    Community Dent Oral Epidemiol; 2004 Jun; 32(3):210-6. PubMed ID: 15151691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada.
    Xie F; O'Reilly D; Ferrusi IL; Blackhouse G; Bowen JM; Tarride JE; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):317-23. PubMed ID: 19394572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient preferences for depression treatment programs and willingness to pay for treatment.
    Morey E; Thacher JA; Craighead WE
    J Ment Health Policy Econ; 2007 Jun; 10(2):73-85. PubMed ID: 17603148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The burden of depressive disorders in Germany - results from the European Study of the Epidemiology of Mental Disorders (ESEMeD)].
    Günther OH; Friemel S; Bernert S; Matschinger H; Angermeyer MC; König HH
    Psychiatr Prax; 2007 Sep; 34(6):292-301. PubMed ID: 17806016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?
    Nimdet K; Chaiyakunapruk N; Vichansavakul K; Ngorsuraches S
    PLoS One; 2015; 10(4):e0122760. PubMed ID: 25855971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.
    Nimdet K; Ngorsuraches S
    BMJ Open; 2015 Oct; 5(10):e008123. PubMed ID: 26438135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caring externalities in health economic evaluation: how are they related to severity of illness?
    Jacobsson F; Carstensen J; Borgquist L
    Health Policy; 2005 Aug; 73(2):172-82. PubMed ID: 15978960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
    Olofsson S; Norrlid H; Persson U
    J Med Econ; 2016 Oct; 19(10):945-58. PubMed ID: 27149402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Willingness to pay for drug abuse treatment: results from a contingent valuation study in Taiwan.
    Tang CH; Liu JT; Chang CW; Chang WY
    Health Policy; 2007 Jul; 82(2):251-62. PubMed ID: 17084480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valuing the benefits of a health intervention using three different approaches to contingent valuation: re-treatment of mosquito bed-nets in Nigeria.
    Onwujekwe O; Fox-Rushby J; Hanson K
    J Health Serv Res Policy; 2004 Apr; 9(2):67-75. PubMed ID: 15099453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Willingness to pay for QALY: perspectives and contexts in Japan.
    Igarashi A; Goto R; Yoneyama-Hirozane M
    J Med Econ; 2019 Oct; 22(10):1041-1046. PubMed ID: 31262236
    [No Abstract]   [Full Text] [Related]  

  • 39. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trying to estimate a monetary value for the QALY.
    Pinto-Prades JL; Loomes G; Brey R
    J Health Econ; 2009 May; 28(3):553-62. PubMed ID: 19327857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.